Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/12/2025

Dual Antiplatelet Therapy with Clopidogrel and Aspirin

Indications for Dual Therapy

  • The American College of Cardiology recommends dual antiplatelet therapy with clopidogrel and aspirin for patients with non-ST-elevation acute coronary syndromes (ACS), reducing cardiovascular death, myocardial infarction (MI), or stroke from 11.4% to 9.3% compared to aspirin alone 1, 2.
  • The American Heart Association suggests that patients with ST-elevation MI treated with fibrinolytics benefit from dual therapy, reducing major cardiovascular events from 10.9% to 9.1% over 30 days 1, 2.
  • Dual antiplatelet therapy is recommended for patients with bare-metal stents for at least 1 month 1, 2, 3 and for patients with drug-eluting stents for at least 12 months 1, 2, 3, 4.

Contraindications and Precautions

  • The American College of Cardiology advises against dual antiplatelet therapy in patients with recent ischemic stroke or transient ischemic attack (TIA), as it shows insignificant benefit but increases life-threatening hemorrhages from 1.3% to 2.6% 1, 2, 3.
  • Primary prevention patients without established cardiovascular disease should not receive dual therapy, as it provides no significant benefit but increases severe bleeding from 1.3% to 1.7% 1, 2, 3.

Mechanism of Action and Bleeding Risk

  • Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production and preventing platelet aggregation through this pathway, while clopidogrel irreversibly blocks the P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation 6.
  • Dual antiplatelet therapy significantly increases bleeding compared to aspirin alone, with major bleeding increasing from 2.7% to 3.7% in ACS patients 1, 2, 3.

Optimal Dosing Strategy and Duration of Therapy

  • The optimal aspirin dose is 75-100 mg daily, which provides equal efficacy with lower bleeding risk than higher doses, and the maintenance dose of clopidogrel is 75 mg daily 6.
  • The loading dose of clopidogrel for ACS patients is 300 mg, and dual therapy should be continued for 12 months maximum unless contraindicated 4, 6.
  • Patients with bare-metal stents require at least 1 month of dual therapy, while those with drug-eluting stents require at least 12 months of dual therapy 1, 2, 4.

Gastrointestinal Protection

  • All patients on dual antiplatelet therapy require gastroprotection, and a proton pump inhibitor (PPI) should be prescribed to reduce GI bleeding risk, with the exception of omeprazole, which should be avoided with clopidogrel due to its inhibition of CYP2C19 4, 7.

REFERENCES